Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

Core Insights - Eton Pharmaceuticals has been added to the Russell 3000 and Russell 2000 Indexes, effective after the U.S. market closes on June 27, 2025, marking a significant milestone for the company [1][2]. Company Overview - Eton Pharmaceuticals is focused on developing and commercializing treatments for rare diseases, currently offering eight commercial products and five additional candidates in late-stage development [4]. Market Impact - The inclusion in the Russell indexes is expected to enhance Eton's visibility among investors and reflects the shareholder value generated over the past year [2][3]. Product Portfolio - Eton's commercial rare disease products include KHINDIVI, INCRELEX, ALKINDI SPRINKLE, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone, with late-stage candidates including ET-600, Amglidia, ET-700, ET-800, and ZENEO hydrocortisone autoinjector [4].